Sing Chan, MD
Gastroenterology · Flushing, NYNPI 1225053523
Payments from drug & device makers
Across 579 payments — averaging $139.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$53K
- AbbVie$21K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Ardelyx, Inc.$956
- Intra-sana Laboratories$494
- Johnson & Johnson$479
- plus $3K from 20 others
Across 2 payments — averaging $1198.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB Biosciences Inc.$1K
- Gilead$1K
What the payments were for
- Food & beverage$10,603100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 176 | $52,877 |
| AbbVie(2 entities) | 84 | $21,471 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 87 | $1,653 |
| Ardelyx, Inc. | 38 | $956 |
| Intra-sana Laboratories | 26 | $494 |
| Johnson & Johnson | 20 | $479 |
| Pfizer | 19 | $453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $381 |
| Ironwood Pharmaceuticals, Inc | 14 | $267 |
| Phathom Pharmaceuticals, Inc. | 10 | $250 |
| Madrigal Pharmaceuticals | 11 | $240 |
| Nestle Healthcare Nutrition Inc. | 10 | $207 |
| Bristol Myers Squibb | 16 | $206 |
| Amgen | 9 | $154 |
| Redhill Biopharma Inc. | 7 | $144 |
| Aimmune Therapeutics, Inc. | 6 | $141 |
| Celltrion USA Inc. | 6 | $141 |
| Intercept Pharmaceuticals, Inc. | 7 | $140 |
| Evoke Pharma, Inc. | 5 | $87 |
| Lilly USA, LLC | 2 | $37 |
| Cumberland Pharmaceuticals, Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| QOL Medical, LLC | 1 | $23 |
| Echosens North America, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$80,907 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbsrelaTenapanor Hcl | 189 | $716,798 |
| VemlidyTenofovir Alafenamide | 348 | $528,198 |
| LinzessLinaclotide | 424 | $232,763 |
| XifaxanRifaximin | 80 | $210,062 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 84 | $148,900 |
| RezdiffraResmetirom | 31 | $135,725 |
| EntyvioVedolizumab | 14 | $119,107 |
| CreonLipase/Protease/Amylase | 68 | $82,000 |
| Ursodiol | 20 | $82,000 |
| ZenpepLipase/Protease/Amylase | 37 | $65,967 |
| VoqueznaVonoprazan Fumarate | 81 | $51,707 |
| Glycopyrrolate | 19 | $35,394 |
| Mesalamine | 131 | $31,949 |
| PentasaMesalamine | 19 | $30,231 |
| Famotidine | 818 | $25,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ardelyx, Inc.Ibsrela | $956 | $716,798189 claims |
| GileadVemlidy | $52,877 | $528,198348 claims |
| AbbVieLinzess, Creon | $21,471 | $314,763492 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,653 | $221,22996 claims |
| Madrigal PharmaceuticalsRezdiffra | $240 | $135,72531 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity | $381 | $133,41138 claims |
| Aimmune Therapeutics, Inc.Zenpep | $141 | $65,96737 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $250 | $51,70781 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Flushing
- Calvin PanFlushing$684K
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Igor GrosmanBrooklyn$2.8M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.